Role of Circulating Tumor DNA Tumor Fraction in Advanced Non–Small Cell Lung Cancer and Its Impact on Patient Treatment Outcomes: A Prospective Real-World Study
Our findings establish ctDNA TF as a clinically relevant biomarker in aNSCLC, providing robust prognostic and predictive information. The findings support the integration of ctDNA TF quantification into routine clinical workflows, reinforcing its role in advancing precision oncology and improving risk stratification and outcomes for patients with aNSCLC.
Authors
- David Shih (ORCID: https://orcid.org/0000-0002-9802-4937)
- Anne W.M. Lee (ORCID: https://orcid.org/0000-0003-2972-0231)
- Dennis Kwok‐Chuen Leung
- Isaac Ho (ORCID: https://orcid.org/0000-0003-2535-0069)
- Aya El Helali (ORCID: https://orcid.org/0000-0001-6427-114X)
- Ben Man Fei Cheung (ORCID: https://orcid.org/0000-0003-0419-6082)
- Jason W.H. Wong (ORCID: https://orcid.org/0000-0003-2953-7728)
- Elaine Yee-Ling Ko (ORCID: https://orcid.org/0009-0005-9442-4756)
- Victor Lee (ORCID: https://orcid.org/0000-0002-6283-978X)
- Matthew Kin-Liang Chiu (ORCID: https://orcid.org/0009-0007-7189-5883)
- Gin Wai Kwok
Institutions
- Chinese University of Hong Kong (HK)
- Queen Mary Hospital (CN)
- Institute of Clinical Research (US)
- University of Hong Kong - Shenzhen Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1200/po-25-00376
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00